Safety Profile – NeuroAiD™

researchers-are-analyzing-data-to-create-scientifi-M4K9SPR-min

ABOUT NEUROAID ▸ CLINIcal studies ▸ safety profile ▸ composition & dosage ▸

ABOUT

NeuroAiD is an oral treatment helping victims of strokes and traumatic brain injuries who suffer from established deficits to recover their functional independence in addition to rehabilitation therapies and exercises.

HOME

ABOUT ▾

library contact

order Medical Professionals
Find out if neuroaid is right for you

Safety Profile

NeuroAiD is safe and well tolerated.

The safety profile of NeuroAiD is now well established. All clinical studies have reported NeuroAiD as a safe product, without severe adverse events and with only rare and transitory gastro-intestinal discomfort (e.g., nausea, vomiting) in subjects with sensitive digestive transit.

NeuroAiD has no impact on hepatic and renal functions, cardiovascular parameters, and other biological parameters^1,2

NeuroAiD is not competing nor interacting with other medications. It can be safely combined to usual post-stroke medications or post-traumatic brain injury medications, and can also be added to other therapeutic products^1,3.

No increase in the rates of delayed adverse events have been reported up to 2 years following a 3-month course with NeuroAiD^4,5.

Always seek advice from your physician.

References

1. . Young S, et al. Safety profile of MLC601 (NeuroAiD) in acute ischemic stroke patients: A Singaporean substudy of the Chinese medicine NeuroAiD efficacy on stroke recovery study. Cerebrovascular Diseases. 2010;30:1-6.
2. Gan R, et al. Danqi Piantan Jiaonang does not modify haemostasis, haematology, and biochemistry in normal subjects and stroke patients. Cerebrovascular Diseases. 2008;25:450-456.
3. Chen C, et al. Chinese medicine NeuroAiD efficacy on stroke recovery: A double-blind, placebo-controlled, randomized study. Stroke. 2013a;44:2093-2100
4. Venketasubramanian N, et al. CHInese medicine NeuroAiD efficacy on stroke recovery – Extension study (CHIMES-E): A multicenter study of long-term efficacy. Cerebrovascular Diseases. 2015;39:309-318.
5. Shahripour RB, et al. A Randomized Trial to Assess the Long-Term Safety of NeuroAiD among Caucasian Patients with Acute Ischemic Stroke. Chin J Integr Med. 2014;20(11): 812-817.

Disclaimers: NeuroAiD™ II is a trademark of Moleac. MLC601 and MLC901 are 2 different proprietary formulations which have been shown to be equivalent in pharmacology and are referred as NeuroAiD on this webpage.

Find-out if NeuroAiD is right for you.

Leave your questions to our Customer Care team by clicking on the box below. Always seek advice from your physician.

ASK YOUR QUESTIONS